TargetMol

Enoximone

Product Code:
 
TAR-T8462
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T8462-1mg1mg£102.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8462-5mg5mg£144.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8462-10mg10mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8462-1mL1 mL * 10 mM (in DMSO)£198.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8462-25mg25mg£282.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8462-50mg50mg£450.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8462-100mg100mg£627.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Enoximone is a selective inhibitor of phosphodiesterase III (PDE3), with treatment of congestive heart failure.
CAS:
77671-31-9
Formula:
C12H12N2O2S
Molecular Weight:
248.3
Pathway:
Metabolism
Purity:
0.9552
SMILES:
CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C
Target:
PDE

References

Emiliano Angeloni , Giovanni Melina , Francesco Federici,et al.Preliminary Results of the Multicenter Observational Study With Enoximone in Cardiac Surgery (MOSEC).Observational Study Int J Cardiol. 2018 Oct 15;269:51-55.